Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mei Shi

Showing results (651-660 of 678) with videos related to

Pageof 68
Sort By:
Blood Advances|September 23, 2018
Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative GroupTao Wu, Yong Yang, Su-Yu Zhu, et al.
The Journal of Clinical Investigation|May 13, 2020
Ribosomal S6 protein kinase 4 promotes radioresistance in esophageal squamous cell carcinomaMing-Yang Li, Lin-Ni Fan, Dong-Hui Han, et al.
Zhonghua Nei Ke Za Zhi|January 19, 2013
[The baseline characteristics of patients with type 2 diabetes initiating insulin detemir : the Chinese cohort from the SOLVE(TM) study]Chang-yu Pan, Li-nong Ji, Ju-ming Lu, et al.
International Journal of Radiation Oncology, Biology, Physics|January 28, 2017
Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2)Loren K Mell, Igor Sirák, Lichun Wei, et al.
Zhonghua Nei Ke Za Zhi|May 29, 2013
[The safety and effectiveness of once daily detemir in patients with type 2 diabetes previously failing oral agents: the Chinese cohort from SOLVE(TM) observational study]Chang-yu Pan, Li-nong Ji, Ju-ming Lu, et al.
Cancer Reports (Hoboken, N.J.)|March 15, 2023
Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphomaJia-Xin Liu, Xin Liu, Yong Yang, et al.
JCO Global Oncology|January 15, 2026
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model-Based Cost-Effectiveness AnalysisJing Yang, Qiu-Zi Zhong, Li-Ting Qian, et al.
Blood Advances|July 14, 2020
First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCGShu-Nan Qi, Yong Yang, Yu-Qin Song, et al.
Leukemia|August 3, 2021
Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) studyYong Yang, Ying Wang, Xin Liu, et al.
Haematologica|March 23, 2023
Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG databaseXin Liu, Li-Ling Zhang, Bao-Lin Qu, et al.
Pageof 68

Showing results (651-660 of 678) with videos related to

Sort By:
Pageof 68
Blood Advances|September 23, 2018
Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative GroupTao Wu, Yong Yang, Su-Yu Zhu, et al.
The Journal of Clinical Investigation|May 13, 2020
Ribosomal S6 protein kinase 4 promotes radioresistance in esophageal squamous cell carcinomaMing-Yang Li, Lin-Ni Fan, Dong-Hui Han, et al.
Zhonghua Nei Ke Za Zhi|January 19, 2013
[The baseline characteristics of patients with type 2 diabetes initiating insulin detemir : the Chinese cohort from the SOLVE(TM) study]Chang-yu Pan, Li-nong Ji, Ju-ming Lu, et al.
International Journal of Radiation Oncology, Biology, Physics|January 28, 2017
Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2)Loren K Mell, Igor Sirák, Lichun Wei, et al.
Zhonghua Nei Ke Za Zhi|May 29, 2013
[The safety and effectiveness of once daily detemir in patients with type 2 diabetes previously failing oral agents: the Chinese cohort from SOLVE(TM) observational study]Chang-yu Pan, Li-nong Ji, Ju-ming Lu, et al.
Cancer Reports (Hoboken, N.J.)|March 15, 2023
Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphomaJia-Xin Liu, Xin Liu, Yong Yang, et al.
JCO Global Oncology|January 15, 2026
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model-Based Cost-Effectiveness AnalysisJing Yang, Qiu-Zi Zhong, Li-Ting Qian, et al.
Blood Advances|July 14, 2020
First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCGShu-Nan Qi, Yong Yang, Yu-Qin Song, et al.
Leukemia|August 3, 2021
Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) studyYong Yang, Ying Wang, Xin Liu, et al.
Haematologica|March 23, 2023
Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG databaseXin Liu, Li-Ling Zhang, Bao-Lin Qu, et al.
Pageof 68